50 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Sunshine Biopharma, Inc. (NASDAQ: SBFM) rose 148% to $3.78. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to Nasdaq at $4.25 per unit.
Wells Fargo Initiates Coverage On C4 Therapeutics with Equal-Weight Rating, Announces Price Target of $25
Wells Fargo analyst Derek Archila initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Equal-Weight rating and announces Price Target of $25.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
C4 Therapeutics Announces 2022 Targets
– Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022–
– IND Clearance Achieved for CFT8634, a Degrader Targeting BRD9; On Track to Initiate Phase 1 Trial in Synovial
B of A Securities Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $54
B of A Securities analyst Chi Fong initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $54.
C4 Therapeutics Q3 EPS $(0.51) Beats $(0.59) Estimate, Sales $8.50M Beat $7.61M Estimate
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.59) by 13.56 percent. This is a 97.09 percent increase over losses of $(17.55) per share from
SVB Leerink Initiates Coverage On C4 Therapeutics with Outperform Rating, Announces Price Target of $67
SVB Leerink analyst Andrew Berens initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Outperform rating and announces Price Target of $67.
